Organizer : GQ

2023

2 years

Partners : Mucular Dystrophy Canada Ataxia Canada

Please note that only teams having submitted an eligible registration will be invited to submit an application.

Génome Québec, Ataxia Canada and Muscular Dystrophy Canada are pleased to announce the launch of the opportunity “Innovative therapies for hereditary ataxias”. This one million dollars funding opportunity aims to bring together researchers from different disciplines to discover or develop innovative therapies that support the following objectives:

  • Addressing the needs of people living with a hereditary ataxia from the group of ataxias covered by Ataxia Canada. Under this request for applications, Muscular Dystrophy Canada aims to finance studies on Friedreich’s ataxia.
  • Supporting the discovery and development of novel therapies using omics approaches (including those to alter the function of one or several genes).
  • Encouraging multidisciplinary research in Quebec, to benefit research on hereditary ataxias.

For more details on the competition requirements, please see the request for applications document below.

Funding Overview

Research teams will develop a research program with concrete activities and deliverables, enabling discovery or development of an innovative therapy for a hereditary ataxia.

This program will finance projects with a total budget from $165,000 up to $330,000 each (no co-funding required).

All applicants must submit their application through Génome Québec. The process will consist of a mandatory registration and an application (see below for the documents).

The important dates and key steps of the application process for this funding opportunity are as follows:

April 28, 2023Competition launch
June 8, 2023Mandatory registration deadline: Please submit the registration form to: tia-ita@genomequebec.com
End of June, 2023Notice of eligibility 
October 3, 2023Application submission deadline: Please submit your application (including the budget) to tia-ita@genomequebec.com
End of November 2023Peer Review
End of February 2023Notice of decision
April 1, 2024Start of project
Mid-AprilTransfer of first installment to projects

All applications must be submitted to Génome Québec. To obtain more details related to the initiative, please contact Annina Spilker, Manager of programs and strategic initiatives, by email at tia-ita@genomequebec.com.